BioNTech
phase tolerable safety profile and encouraging pharmacodynamic signals with at all doses previously received i pyrexia grades non serious in of patients | BioNTech
Company
Deck Type
Sector
Industry
Deck date
November 2021
Slide
30 of 40
Related slides by other companies
ATAI
Investor Presentation
January 2024
results from completed phase sad study showed had a favorable safety profile and was well tolerated whilst demonstrating dose proportionate profile | ATAI
ATAI
Investor Presentation
October 2023
is well tolerated with a favorable safety profile demonstrated across clinical studies in patients dosed including up to the highest single dose of and daily dose of tid in two placebo controlled phase studies in over patients was dosed up to tid for six months rates of headache and gastrointestinal issues were comparable to placebo representing a differentiated profile from certain competitor programs in development for does not induce sedation which is distinct from agonists initial phase a study confirmed safety and tolerability profile in schizophrenia patients including on top of standard of care with no evidence of safety concerns on any of the safety measures labs physical exam vitals aes | ATAI
BioAtla
Investor Presentation
August 2023
cab cell engager a | BioAtla
Matinas BioPharma
Investor Presentation
January 2024
enact phase clinical validation of safety and efficacy | Matinas BioPharma
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io